Tag
The abrupt recall of a new treatment for sickle cell disease serves as a reminder of why journalists should avoid…

This finding is a reminder for journalists to inquire whether clinician sources have financial disclosures that might bias their views.

The Trump administration has been talking tough on drug prices for many months and, of course, pharmaceutical companies and other…

Investigative journalist Katherine Eban will discuss her new book documenting rampant fraud in the generic drug industry during an AHCJ…

The registration and reporting requirements of Clinicaltrials.gov are vital to informing the evidence base – but only if study sponsors…

•
When newly installed Health and Human Services Secretary Alex Azar held one of his first meetings with the media on…

•
About 25 journalists gathered on March 18 at Bistro d’Oc in Washington, D.C., for an AHCJ chapter happy hours event…

•
Health journalists received a few lessons in economics during a discussion last week on some alarming drug trends – largely…

•
Reporters curious about the financial relationship between physicians and pharmaceutical companies can use publicly available data as a starting point…

•
When The Cincinnati Enquirer set out to look at the societal costs of the deadly opioid crisis, reporter Lisa Bernard-Kuhn…
